- About us
- Clinical Trials
- News & Publications
- Business Development
The knowledge that dendritic cells play a central role in initiating the human body’s immune response and the capability of producing them in vitro in large quantities have led researchers to consider using them in cancer immunotherapy.
SOTIO’s process involves a personalized preparation of the drug, tailored to a specific patient. Tumor cells (from cancer cell lines) killed by High Hydrostatic Pressure (HHP), physical modality inducing immunogenic cell death, are used as the source of broad range of tumor antigens. These are then incubated with dendritic cells cultivated from the patient’s blood monocytes. Apoptotic tumor cells are engulfed by immature dendritic cells are subsequently activated. Mature DCs present tumor antigens and are reintroduced into the patient’s body in the form of immunotherapeutic vaccine to trigger the required response from the patient’s immune system against the harmful tumor cells.
In line with both expert theoretical assumptions and experimental data, cancer immunotherapy solely on its own has the greatest chance of success if applied to patients at the early stages of the disease, or to patients following a radical surgical intervention when a large amount of the tumor tissue has been removed.
In advanced stages of the disease, cancer immunotherapy needs to be combined with other therapies. For example, it has been shown that immunotherapy and chemotherapy need not be mutually exclusive, but that a suitable combination of both can have a positive effect. One of the reasons for this is thought to be the fact that chemotherapy reduces the level of T-regulatory lymphocytes, which support tumor growth because they actively suppress the anti-tumor immune response.
The immunotherapy treatment pursued by SOTIO is focused on combining immunotherapy with chemotherapy and other standard therapies with a view to boosting the efficiency of its drug.
Scientific findings in the field of prostate and ovarian cancer immunology, published by SOTIO’s researchers in many scientific publications (List of Publications), are being applied in the currently running Phase II and III clinical trials for prostate carcinoma therapy, and in a Phase II clinical trial for ovarian cancer therapy. Recently, the scientific team has begun pursuing a preclinical study of lung carcinoma, and arranging protocols for treatment of the disease.
SOTIO’s research team is also participating in treatment success rate monitoring in individual clinical trials. Using the latest detection methods of molecular biology and cancer immunology, the team is studying the immune response of individual patients to antineoplastic therapy. The data gathered, which are also being published, are valuable in verifying therapeutic effectiveness in patients.
SOTIO’s research has recently focused also on development of new medicinal products designed to treat autoimmune disease.
The results discovered by our scientific research team are regularly published in leading scientific journals with impact factor (IF) (List of Publications) and presented at prestigious scientific and medical conferences. The research team works in collaboration with some leading research centers studying cancer immunology, cell apoptosis, immunogenic cell death, and autoimmunity issues. Among these prominent research centers are: